Emergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary
ABT
ABT, ERIC, IVZ
CVX, PFE
BIIB
JNJ
David H. Toung
Senior Analyst: Medical Devices & Healthcare Services